- Home
- AVIR
as 11-21-2024 4:00pm EST
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 276.9M | IPO Year: | 2020 |
| Target Price: | $6.88 | AVG Volume (30 days): | 178.7K |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.07 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.81 - $4.60 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Atea Pharmaceuticals Inc. (AVIR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Sommadossi Jean-Pierre | AVIR | President, CEO, and Chairman | Sep 17 '24 | Sell | $4.03 | 57,969 | $234,155.07 | 5,890,053 |
Latest Atea Pharmaceuticals Inc. News
AVIR Breaking Stock News: Dive into AVIR Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024
GuruFocus.com
10 days ago
Atea Pharmaceuticals Inc (AVIR) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ...
GlobeNewswire
14 days ago
Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
21 days ago
Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024
GlobeNewswire
22 days ago
Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024
Simply Wall St.
a month ago
Atea Pharmaceuticals Leads The Charge In US Penny Stocks Spotlight
Zacks
a month ago
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
GuruFocus.com
a month ago
Atea Pharmaceuticals Inc (AVIR) Q2 2024 Earnings Call Highlights: Strong Financial Position and ...
Compare AVIR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AVIR Atea Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.